



Dkt. 0857/70669/JPW/LAD

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Anne Marie Rodriguez et al.  
Serial No.: 10/632,581 Examiner: J. Hama, Ph.D.  
Filed : July 31, 2003 Group Art Unit: 1632  
For : STEM CELLS ORIGINATING FROM ADIPOSE TISSUE AND  
DIFFERENTIATED CELLS DERIVED FROM THESE STEM CELLS

1185 Avenue of the Americas  
New York, New York 10036  
March 31, 2008

Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**AMENDMENT IN RESPONSE TO FEBRUARY 27, 2007 FINAL OFFICE ACTION,  
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT AND PETITION FOR A FIVE-  
MONTH EXTENSION OF TIME AS A SUBMISSION UNDER 37 C.F.R. §1.114(C)  
ACCOMPANYING A REQUEST FOR CONTINUED EXAMINATION**

This Amendment is a submission under 37 C.F.R. §1.114(c) accompanying an RCE and responds to a February 27, 2007 Final Office Action issued by the U.S. Patent and Trademark Office in connection with the above-identified application. A response to the February 27, 2007 Final Office Action was originally due May 27, 2007. Applicants mailed a Notice of Appeal and Petition for Three-Month Extension Of Time to the U.S. Patent Office on August 27, 2007, which was received on August 30, 2007. As a result an appeal brief was initially due October 30, 2007. Applicants hereby petition for a five-month extension of time. The required fee for a five-month extension of time is TWO THOUSAND TWO HUNDRED AND THIRTY DOLLARS (\$2,230.00) and a check including this amount is enclosed. With a five-month extension of time, a response is due March 30, 2008. However, since March 30, 2008 falls on a Sunday, a response filed Monday, March 31, 2008, i.e. the next business day, shall be considered timely. Accordingly, the RCE and

Applicants: Anne Marie Rodriguez, et al.  
Serial No.: 10/632,581  
Filed : July 31, 2003  
Page 2

this Amendment are being timely filed.

**Amendments to the claims** begin on page 3 of this paper.

**Remarks** begin on page 8 of this paper.

A **Supplemental Information Disclosure Statement** begins on page 17 of this paper.